The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

The weight loss conversation has been transformed in recent years by the rise of GLP-1 medications—drugs originally developed for diabetes that are now being used to help people lose significant ...

RDX-002, a novel iMTP inhibitor, showed promising results in a Ph2 study, reducing blood fat and weight regain after GLP-1 ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...